About PharmXnext
PharmXnext is a company based in Mumbai (India) founded in 2017 by Ankush Kapoor and Amod Pandit. It operates as a B2B and Direct Sales. The company has 40 employees. PharmXnext offers products and services including XELTA 2D, XELTA 3D, NXTmix, NXTchrom, and NXTtff. PharmXnext operates in a competitive market with competitors including Cepheid, Esco Lifesciences, Beckman Coulter, Blackrock Neurotech and Waters Corporation, among others.
- Headquarter Mumbai, India
- Employees 40
- Founders Ankush Kapoor, Amod Pandit
- SectorsHealthcare
- Email••••••••
- Website pharmnxtbiotech.com
- Legal Name Pharmnxt Ekuse Private Limited
- Date of Incorporation 23 Nov, 2021
- Jurisdiction Thane, Maharashtra, India
- Annual Revenue₹30.30 Cr
FY 2025 · +408% YoY
- Net Loss-₹2.75 Cr
FY 2025 · -9% margin
- EBITDA-₹2.19 Cr
FY 2025 · -7% margin
- Employee Count40
Associated legal entities of PharmXnext
PharmXnext is associated with 2 registered companies on The Company Check; the primary company is Pharmnxt Ekuse Private Limited. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Pharmnxt Ekuse Private Limited CIN U29308MH2021PTC372043 | Active | 23 Nov 2021 | Thane, Maharashtra | ₹30.3 Cr | 40 | 3 | View details |
| Pharmnxt Biotech Llp CIN AAJ-9018 | Active | 05 Jul 2017 | Thane, Maharashtra | ₹31.9 Cr | 27 | 3 | View details |
Products & Services of PharmXnext
PharmXnext offers a comprehensive portfolio of products and services, including XELTA 2D, XELTA 3D, NXTmix, NXTchrom, and NXTtff.
Provides reliable 2D storage bags for biopharmaceutical fluid handling.
Offers large-scale 3D storage bags for pharmaceutical manufacturing processes.
Delivers levitation-based mixing technology for media preparation and formulation.
Facilitates configurable systems for purification in bioprocess applications.
Enables automated tangential flow filtration for high-capacity bioprocessing.
Board of directors of Pharmnxt Ekuse Private Limited (PharmXnext)
Pharmnxt Ekuse Private Limited is the primary company behind PharmXnext. The boards of the 2 registered companies of PharmXnext currently have 3 directors; the longest-serving is Ankush Kapoor, appointed in 2017. 3 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Ankush Kapoor DIN 07802596 | Designated Partner | 05 Jul 2017 | 9 yrs 3 mo | Pharmnxt Biotech Llp, Pharmnxt Ekuse Private Limited |
| Nandkumar Vasant Thakare DIN 09134440 | Designated Partner | 01 Apr 2021 | 5 yrs 6 mo | Pharmnxt Biotech Llp, Pharmnxt Ekuse Private Limited |
| Sachin Satish Joshi DIN 09134418 | Designated Partner | 01 Apr 2021 | 5 yrs 6 mo | Pharmnxt Biotech Llp, Pharmnxt Ekuse Private Limited |
People of PharmXnext
2 people are tracked at PharmXnext (2 in leadership); the tracked headcount is 40.
| Name | Role | Group |
|---|---|---|
| Co-Founder | Leadership | |
Amod Pandit | Co-Founder | Leadership |
Complete people profiles for PharmXnext
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of PharmXnext
Figures of Pharmnxt Ekuse Private Limited, the primary company behind PharmXnext, for FY 2025. Revenue was ₹30.30 Cr (+408% year on year). Net loss was -₹2.75 Cr (-9% margin). EBITDA was -₹2.19 Cr (-7% margin). Revenue has grown at a compounded annual rate of +1309% over three years.
- ₹30.30 CrRevenue · FY 2025 · +408% YoY
- -₹2.75 CrNet loss · -9% margin
- -₹2.19 CrEBITDA · -7% margin
- ₹3.60 CrPaid-up capital
- 40Employees (provident fund records)
- +1309%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Pharmnxt Ekuse Private Limited are on its company page.
Detailed financial statements for PharmXnext
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of PharmXnext
PharmXnext operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cepheid, Esco Lifesciences, Beckman Coulter, Blackrock Neurotech and Waters Corporation, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cepheid.com | 1996 | Sunnyvale, United States | $19.1M | 1,299 | Developer of molecular diagnostic testing solutions | |
| escolifesciences.com | 1978 | Singapore | $400M | – | Manufacturer of biopharma equipment & IVF medical devices, and service provider for life science tools | |
| beckman.com | 1935 | Brea, United States | – | – | Provider of products for biomedical testing for R&D, diagnostic and commercial applications | |
| blackrockneurotech.com | 2008 | Salt Lake, United States | $22.37M | 127 | Medical devices for neurological therapies are developed. | |
| waters.com | 1958 | Milford, United States | – | 9,341 | Provider of laboratory management system for researchers and clinicians | |
| fluidigm.com | 1999 | San Francisco, United States | $40.53M | 205 | Instruments for life sciences research and applications are developed. | |
| bruker.com | 1960 | United States | – | 9,707 | Diversified research instrument systems are manufactured and supplied. | |
| sartorius.com | 1870 | Gottingen, Germany | – | 566 | Laboratory and biopharmaceutical equipment is developed for production processes. | |
| unchainedlabs.com | 2015 | Pleasanton, United States | $111M | – | Multiplex protein stability platform for biologics is developed. |
Detailed competitors of PharmXnext
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of PharmXnext
The website of PharmXnext (pharmnxtbiotech.com) receives about 1.5K visits a month.
- Monthly visits1.5K
Latest news on Pharmxnext
Complete news archive for PharmXnext
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to PharmXnext
10 companies that operate in the same segment as PharmXnext (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about PharmXnext
PharmXnext was founded in 2017.
PharmXnext is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
PharmXnext has 40 employees.
The primary company behind PharmXnext, Pharmnxt Ekuse Private Limited, reported revenue of ₹30.30 Cr for FY 2025, up 408% year on year.
PharmNXT Biotech specializes in developing and manufacturing single-use technologies, including storage bags, mixing systems, and chromatography equipment for the biopharmaceutical industry. They provide end-to-end solutions such as process equipment and services like installation, qualification, and maintenance. Based in India with offices in Singapore and South Korea, they support biologics manufacturing for applications in mRNA and cell gene therapy, partnering with global entities to ensure reliable and flexible systems.
PharmXnext's top competitors include Cepheid, Blackrock Neurotech and Esco Lifesciences.
PharmXnext offers XELTA 2D, XELTA 3D, NXTmix, NXTchrom, and NXTtff.
PharmXnext is associated with 2 legal entities: Pharmnxt Ekuse Private Limited, Pharmnxt Biotech Llp.
The legal entities of PharmXnext currently have 3 directors, including Nandkumar Vasant Thakare, Sachin Satish Joshi, Ankush Kapoor.